Observed on June 20, World FSHD Day is a global movement to raise awareness of Facioscapulohumeral Muscular Dystrophy (FSHD), one of the most common forms of muscular dystrophy. On this […]
The FSHD community received encouraging news today as Novartis announced that delpacibart braxlosiran (del-brax) met the primary and key secondary endpoints in the biomarker cohort of the Phase 1/2 FORTITUDE […]
The FSHD Society is deeply grateful to Kent and Sue Drescher for their years of dedicated service as leaders of the Bay Area Chapter. On Sunday, May 22, they officially […]
The FSHD Industry Collaborative is a first-of-its-kind, multi-stakeholder initiative designed to improve how FSHD clinical trials are designed, executed, and evaluated RANDOLPH, Mass. and VANCOUVER, BC, April 8, 2026 /PRNewswire/ […]
Dr. Lucienne Ronco, Chief Science Officer of the FSHD Society Originally published on March 19, 2026 Edited for clarity as of March 20, 2026 Today we received news that Roche […]
English English 
العربية
Español de México
Français du Canada
简体中文
